来自官方财务报表的收入、利润与现金流历史。
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹67.2B | ₹55.1B | ₹50.0B | ₹60.1B | — |
| 毛利 | ₹39.6B | ₹29.7B | ₹25.0B | ₹31.7B | — |
| 营业利润（EBIT） | ₹13.1B | ₹6.3B | ₹3.9B | ₹12.9B | — |
| 净利 | ₹8.9B | ₹3.6B | ₹1.6B | ₹7.9B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 LAURUSLABS 交互式查看器。 /companies/us/LAURUSLABS
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms